Hefei Medical and Pharmaceutical

Hefei Medical and Pharmaceutical Co., Ltd. is an active Chinese pharmaceutical company founded in Anhui province in 1994, specializing primarily in the research and development of small-molecule chemical drugs. The company's pipeline includes at least eight programs targeting indications such as allergic rhinitis (desloratadine citrate disodium, approved), acute fever (ibuprofen, phase 3), atopic dermatitis (HY-072808, phase 3), and acute ischemic stroke (pyragrel sodium). Its main therapeutic focus spans immune-related disorders, CNS conditions, infectious disease, dermatology/musculoskeletal issues, and cardiovascular health. No evidence was found that it operates proprietary platform technologies or has been acquired by another entity. The firm remains privately held with headquarters in Hefei City.